Analytical methods | |||||||
---|---|---|---|---|---|---|---|
Comparative study | #1 | #2 | #3 | #4 | #5 | #6 | |
Chromatography | LC | LC | LC | LC | LC | LC | |
Ion source | ESI | ESI | ESI | ESI | ESI | ESI | |
Positive/Negative mode | both | both | both | both | both | both | |
Mass analyzer | Q-TOF | Q-TOF | Q-TOF | Q-TOF | Q-TOF | Q-TOF | |
Identification level | – | – | – | – | – | – |
Sample information | |||||||
---|---|---|---|---|---|---|---|
Comparative study | #1 | #2 | #3 | #4 | #5 | #6 | |
Country | Poland | Poland | Poland | Poland | Poland | Poland | |
Specimen | Tissue | Tissue | Tissue | Plasma | Plasma | Plasma | |
Marker function | diagnosis | diagnosis | diagnosis | diagnosis | diagnosis | diagnosis | |
Participants(Case) | Cancer type | adenocarcinoma (ADC) | squemous cell carcinoma (SCC) | squemous cell carcinoma (SCC) | adenocarcinoma (ADC) | squemous cell carcinoma (SCC) | squemous cell carcinoma (SCC) |
Stage | I, II, III | I, II, III | I, II, III | I, II, III | I, II, III | I, II, III | |
Number | 33 | 54 | 54 | 32 | 33 | 33 | |
Gender (M,F) | 23, 10 | 39, 15 | 39, 15 | 20, 12 | 21, 12 | 21, 12 | |
Mean age (range) (M,F) | 64.77 ± 8.44 | 64.45 ± 8.02 | 64.45 ± 8.02 | 64.16 ± 6.91 | 64.45 ± 8.77 | 64.45 ± 8.77 | |
Smoking status | – | – | – | – | – | – | |
Participants(Control) | Type | healthy control | healthy control | adenocarcinoma (ADC) | healthy control | healthy control | adenocarcinoma (ADC) |
Number | 20 | 20 | 33 | 20 | 20 | 32 | |
Gender (M,F) | 13, 7 | 13, 7 | 23, 10 | 13, 7 | 13, 7 | 20, 12 | |
Mean age (range) (M,F) | 61.5 ± 12.06 | 61.5 ± 12.06 | 64.77 ± 8.44 | 61.5 ± 12.06 | 61.5 ± 12.06 | 64.16 ± 6.91 | |
Smoking status | – | – | – | – | – | – |
Data processing and metabolite identification | |
---|---|
Data processing software | Mass Hunter Qualitative Analysis Software, Mass Profiler Professional |
Database search | METLIN, KEGG, LIPIDMAPS, and HMDB |
Statistical analysis | |
---|---|
Differential analysis method | Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) |
Classification method | – |
Survival analysis method | – |
Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
---|---|---|---|---|---|---|---|
arginine | – | – | – | – | 0.02 | – | – |
glutamic acid | – | – | – | – | 6.95e-03 | – | – |
glutamic acid | – | – | – | – | 0.03 | – | – |
glutamic acid | – | – | – | – | 5.85e-03 | – | – |
glutamine | – | – | – | – | 0.04 | – | – |
histidine | – | – | – | – | 3.35e-05 | – | – |
histidine | – | – | – | – | 1.48e-03 | – | – |
histidine | – | – | – | – | 7.84e-04 | – | – |
leucine/isoleucine | – | – | – | – | 1.88e-03 | – | – |
phenylalanine | – | – | – | – | 2.08e-05 | – | – |
proline | – | – | – | – | 1.24e-04 | – | – |
proline | – | – | – | – | 1.93e-04 | – | – |
proline | – | – | – | – | 2.16e-04 | – | – |
tryphophan | – | – | – | – | 2.25e-06 | – | – |
tyrosine | – | – | – | – | 0.05 | – | – |
methylhistidine | – | – | – | – | 3.71e-03 | – | – |
acetylaspartic acid | – | – | – | – | 1.54e-03 | – | – |
pyroglutamic acid | – | – | – | – | 1.27e-03 | – | – |
pyroglutamic acid | – | – | – | – | 0.03 | – | – |
taurine | – | – | – | – | 8.18e-04 | – | – |
taurine | – | – | – | – | 1.58e-03 | – | – |
taurine | – | – | – | – | 3.83e-03 | – | – |
glutathione | – | – | – | – | 0.02 | – | – |
glutathione | – | – | – | – | 9.47e-03 | – | – |
glutathione | – | – | – | – | 5.15e-04 | – | – |
guanosine | – | – | – | – | 0.03 | – | – |
guanosine monophosphate | – | – | – | – | 3.27e-08 | – | – |
inosine | – | – | – | – | 5.96e-03 | – | – |
uracil | – | – | – | – | 6.61e-04 | – | – |
uridine monophosphate (UMP) | – | – | – | – | 6.90e-08 | – | – |
uridine diphosphate glucose | – | – | – | – | 1.73e-05 | – | – |
adenosine monophosphate | – | – | – | – | 6.76e-05 | – | – |
methylthioadenosine | – | – | – | – | 2.12e-04 | – | – |
methylthioadenosine | – | – | – | – | 2.70e-04 | – | – |
oxidized glutathione | – | – | – | – | 3.69e-05 | – | – |
xantine | – | – | – | – | 0.01 | – | – |
hypoxanthine | – | – | – | – | 1.02e-03 | – | – |
L-threonic acid/hypoxanthine | – | – | – | – | 3.21e-03 | – | – |
lactic acid | – | – | – | – | 0.02 | – | – |
aminobutyric acid | – | – | – | – | 3.37e-03 | – | – |
acetylneuraminic acid | – | – | – | – | 0.02 | – | – |
Dipicolinic acid (DPA) | – | – | – | – | 2.12e-06 | – | – |
lactic acid | – | – | – | – | 5.62e-06 | – | – |
malic acid | – | – | – | – | 3.46e-05 | – | – |
uric acid | – | – | – | – | 5.03e-03 | – | – |
AMDA | – | – | – | – | 3.87e-03 | – | – |
bilirubin | – | – | – | – | 5.82e-05 | – | – |
bilirubin | – | – | – | – | 4.12e-05 | – | – |
creatinine | – | – | – | – | 2.32e-03 | – | – |
creatine | – | – | – | – | 1.62e-04 | – | – |
creatine | – | – | – | – | 3.53e-03 | – | – |
dihydrothymine | – | – | – | – | 0.04 | – | – |
dimethylglycine | – | – | – | – | 4.23e-03 | – | – |
ethanolamine phosphate | – | – | – | – | 3.20e-05 | – | – |
ethanolamine phosphate | – | – | – | – | 4.19e-06 | – | – |
phosphoethanolamine | – | – | – | – | 2.38e-04 | – | – |
niacinamide | – | – | – | – | 4.27e-05 | – | – |
nicotinamide | – | – | – | – | 3.31e-04 | – | – |
stearamide | – | – | – | – | 0.03 | – | – |
trimethylamine | – | – | – | – | 0.04 | – | – |
glucose-6-phosphate | – | – | – | – | 0.03 | – | – |
diacetylspermine | – | – | – | – | 2.75e-03 | – | – |
acetylspermidine | – | – | – | – | 1.62e-05 | – | – |
phytosphingosine | – | – | – | – | 0.02 | – | – |
sphingosine | – | – | – | – | 9.20e-03 | – | – |
sphingosine | – | – | – | – | 2.17e-03 | – | – |
Glycerophospho-N-hexadecenyl Ethanolamine | – | – | – | – | 0.02 | – | – |
adrenic acid | – | – | – | – | 6.90e-03 | – | – |
arachidonic acid | – | – | – | – | 0.04 | – | – |
arachidonic acid | – | – | – | – | 0.02 | – | – |
arachidonic acid | – | – | – | – | 0.05 | – | – |
docosahexaenoic acid | – | – | – | – | 1.21e-03 | – | – |
eicosadienoic acid | – | – | – | – | 4.89e-05 | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | 1.59e-05 | – | – |
oleic acid | – | – | – | – | 0.01 | – | – |
palmitic acid | – | – | – | – | 0.02 | – | – |
arachidoyl carnitine | – | – | – | – | 0.01 | – | – |
arachidonoylcarnitine | – | – | – | – | 0.02 | – | – |
butyrylcarnitine | – | – | – | – | 3.75e-04 | – | – |
butyrylcarnitine | – | – | – | – | 0.01 | – | – |
eicosadienoylcarnitine | – | – | – | – | 8.91e-03 | – | – |
docosadienoylcarnitine | – | – | – | – | 3.69e-03 | – | – |
eicoseneoylcarnitine | – | – | – | – | 5.29e-03 | – | – |
heptadecanoyl carnitine | – | – | – | – | 0.02 | – | – |
hexadecanoylcarnitine | – | – | – | – | 4.32e-03 | – | – |
Hexadecenoylcarnitine | – | – | – | – | 1.31e-03 | – | – |
hydroxyhexanoylcarnitine | – | – | – | – | 0.04 | – | – |
hydroxyoctadecenoylcarnitine | – | – | – | – | 0.02 | – | – |
hydroxyvalerylcarnitine | – | – | – | – | 1.49e-03 | – | – |
octadecadienylcarnitine | – | – | – | – | 0.01 | – | – |
Octadecenoylcarnitine | – | – | – | – | 0.01 | – | – |
octanoylcarnitine | – | – | – | – | 0.04 | – | – |
Pentadecanoylcarnitine | – | – | – | – | 6.69e-03 | – | – |
stearoylcarnitine | – | – | – | – | 6.21e-03 | – | – |
tetradecanoylcarnitine | – | – | – | – | 0.02 | – | – |
Tetradecenoylcarnitine | – | – | – | – | 9.99e-03 | – | – |
valerylcarnitine | – | – | – | – | 0.02 | – | – |
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0) | – | – | – | – | 1.63e-03 | – | – |
LysoPA 18:1 | – | – | – | – | 8.73e-04 | – | – |
LysoPC 14:0 | – | – | – | – | 0.03 | – | – |
LysoPC 14:0 | – | – | – | – | 0.04 | – | – |
LysoPC 15:0 | – | – | – | – | 1.81e-03 | – | – |
LysoPC 15:0 | – | – | – | – | 3.30e-03 | – | – |
LysoPC 16:0 | – | – | – | – | 9.75e-03 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 9.16e-03 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 0.01 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 0.01 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.03 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.03 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.02 | – | – |
LysoPC 16:1 sn1 | – | – | – | – | 3.92e-04 | – | – |
LysoPC 16:1 sn2 | – | – | – | – | 5.22e-03 | – | – |
LysoPC 16:1 sn2 | – | – | – | – | 0.01 | – | – |
LysoPC 17:0 | – | – | – | – | 0.02 | – | – |
LysoPC 17:0 | – | – | – | – | 0.04 | – | – |
LysoPC 18:1 sn1 | – | – | – | – | 0.03 | – | – |
LysoPC 18:1 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 18:1 sn2 | – | – | – | – | 4.44e-03 | – | – |
LysoPC 18:2 | – | – | – | – | 8.15e-03 | – | – |
LysoPC 18:2 sn1 | – | – | – | – | 0.01 | – | – |
LysoPC 18:2 sn1 | – | – | – | – | 7.28e-03 | – | – |
LysoPC 18:2 sn2 | – | – | – | – | 7.86e-04 | – | – |
LysoPC 18:2 sn2 | – | – | – | – | 1.06e-03 | – | – |
LysoPC 20:2 | – | – | – | – | 6.56e-03 | – | – |
LysoPC 20:2 | – | – | – | – | 8.06e-03 | – | – |
LysoPC 20:3 | – | – | – | – | 9.79e-03 | – | – |
LysoPC 20:3 sn1 | – | – | – | – | 9.05e-03 | – | – |
LysoPC 20:3 sn2 | – | – | – | – | 1.41e-04 | – | – |
LysoPC 20:4 | – | – | – | – | 0.02 | – | – |
LysoPC 20:4 | – | – | – | – | 8.08e-03 | – | – |
LysoPC 22:6 sn1 | – | – | – | – | 2.81e-03 | – | – |
LysoPC 22:6 sn1 | – | – | – | – | 5.54e-04 | – | – |
LysoPC 22:6 sn2 | – | – | – | – | 5.33e-05 | – | – |
LysoPC 22:6 sn2 | – | – | – | – | 4.01e-04 | – | – |
LysoPE 18:2 sn2 | – | – | – | – | 8.85e-04 | – | – |
LysoPE 22:5 | – | – | – | – | 0.01 | – | – |
LysoPE P-16:0 | – | – | – | – | 0.02 | – | – |
LysoPE P-17:0 | – | – | – | – | 0.03 | – | – |
LysoPG 18:0 | – | – | – | – | 0.05 | – | – |
LysoPG 18:1 sn1 | – | – | – | – | 0.02 | – | – |
LysoPG 18:1 sn2 | – | – | – | – | 1.28e-05 | – | – |
LysoPG 18:2 | – | – | – | – | 0.04 | – | – |
LysoPG 20:4 | – | – | – | – | 0.03 | – | – |
LysoPG 22:6 | – | – | – | – | 0.04 | – | – |
LysoPI 16:0 | – | – | – | – | 7.60e-03 | – | – |
LysoPI 18:0 | – | – | – | – | 0.04 | – | – |
LysoPI 18:1 sn1 | – | – | – | – | 8.12e-03 | – | – |
LysoPI 18:2 | – | – | – | – | 6.95e-03 | – | – |
LysoPI 20:3 | – | – | – | – | 0.03 | – | – |
LysoPI 20:3 sn2 | – | – | – | – | 8.79e-03 | – | – |
LysoPI 20:4 sn2 | – | – | – | – | 2.91e-04 | – | – |
PC 14:0/18:2; PC 16:1/16:1 | – | – | – | – | 8.89e-03 | – | – |
PC 14:0/22:6 | – | – | – | – | 1.20e-03 | – | – |
PC 15:0/20:4 | – | – | – | – | 0.02 | – | – |
PC 16:0/18:2 | – | – | – | – | 0.01 | – | – |
PC 16:1/20:4 | – | – | – | – | 9.46e-03 | – | – |
PC 16:1/22:6 | – | – | – | – | 3.44e-04 | – | – |
PC 17:0/20:4 | – | – | – | – | 0.03 | – | – |
PC 18:0/22:6 | – | – | – | – | 8.74e-03 | – | – |
PC 18:1/22:6 | – | – | – | – | 3.17e-03 | – | – |
PC 18:1/22:6 | – | – | – | – | 3.32e-03 | – | – |
PC 18:2/22:6 | – | – | – | – | 0.02 | – | – |
PC 18:2/22:6 | – | – | – | – | 0.04 | – | – |
PC 20:4/14:0 | – | – | – | – | 0.03 | – | – |
PC 20:4/22:4 | – | – | – | – | 4.77e-04 | – | – |
PC 29:0 | – | – | – | – | 0.02 | – | – |
PC 34:1 Plasm | – | – | – | – | 3.31e-03 | – | – |
PC 35:1 | – | – | – | – | 9.01e-03 | – | – |
PC 35:5 | – | – | – | – | 1.70e-03 | – | – |
PC 36:6 | – | – | – | – | 5.45e-04 | – | – |
PC 38:3 | – | – | – | – | 4.77e-03 | – | – |
PC 38:3 | – | – | – | – | 0.01 | – | – |
PC 38:5 | – | – | – | – | 5.07e-03 | – | – |
PC 38:5 | – | – | – | – | 0.01 | – | – |
PC 40:6 | – | – | – | – | 0.02 | – | – |
PC 40:6 Plasm | – | – | – | – | 0.04 | – | – |
PC 40:8 | – | – | – | – | 3.22e-03 | – | – |
PC 40:9 | – | – | – | – | 2.10e-03 | – | – |
PC 42:8 | – | – | – | – | 0.01 | – | – |
PC P-18:0/22:6 | – | – | – | – | 0.03 | – | – |
PC P-18:1/20:4 | – | – | – | – | 0.02 | – | – |
PE 16:0/22:6 | – | – | – | – | 0.03 | – | – |
PE 17:0/20:4 | – | – | – | – | 1.16e-03 | – | – |
PE 32:2 | – | – | – | – | 0.03 | – | – |
PE 36:5 | – | – | – | – | 5.83e-04 | – | – |
SM 32:1 | – | – | – | – | 4.03e-03 | – | – |
SM 35:1 | – | – | – | – | 0.02 | – | – |
SM 35:1 | – | – | – | – | 3.14e-03 | – | – |
SM (d18:1/18:0) | – | – | – | – | 4.12e-03 | – | – |
SM(d18:0/16:0) | – | – | – | – | 6.36e-03 | – | – |
SM(d18:1/12:0) | – | – | – | – | 3.33e-04 | – | – |
SM(d18:1/12:0) | – | – | – | – | 1.58e-04 | – | – |
SM(d18:2/14:0) | – | – | – | – | 8.32e-03 | – | – |
SM(d18:2/14:0) | – | – | – | – | 0.02 | – | – |
SM(d18:2/15:0) | – | – | – | – | 0.01 | – | – |
glutamic acid | – | – | – | – | 1.28e-04 | – | – |
glutamic acid | – | – | – | – | 1.95e-03 | – | – |
glutamic acid | – | – | – | – | 0.02 | – | – |
glutamine | – | – | – | – | 0.02 | – | – |
histidine | – | – | – | – | 0.01 | – | – |
histidine | – | – | – | – | 4.04e-03 | – | – |
histidine | – | – | – | – | 0.02 | – | – |
leucine | – | – | – | – | 1.57e-03 | – | – |
leucine/isoleucine | – | – | – | – | 7.42e-03 | – | – |
phenylalanine | – | – | – | – | 2.01e-04 | – | – |
phenylalanine | – | – | – | – | 2.82e-03 | – | – |
proline | – | – | – | – | 2.01e-03 | – | – |
proline | – | – | – | – | 9.96e-04 | – | – |
proline | – | – | – | – | 9.59e-05 | – | – |
tryphophan | – | – | – | – | 2.92e-06 | – | – |
tyrosine | – | – | – | – | 0.03 | – | – |
valine | – | – | – | – | 1.39e-03 | – | – |
methylhistidine | – | – | – | – | 4.08e-03 | – | – |
acetylaspartic acid | – | – | – | – | 0.03 | – | – |
pyroglutamic acid | – | – | – | – | 5.61e-03 | – | – |
hydroxyglutaric acid | – | – | – | – | 8.60e-04 | – | – |
betaina | – | – | – | – | 2.94e-03 | – | – |
betaine | – | – | – | – | 0.03 | – | – |
taurine | – | – | – | – | 0.02 | – | – |
glutathione | – | – | – | – | 2.32e-03 | – | – |
glutathione | – | – | – | – | 1.06e-03 | – | – |
glutathione | – | – | – | – | 7.97e-04 | – | – |
guanosine | – | – | – | – | 3.26e-04 | – | – |
guanosine monophosphate | – | – | – | – | 1.73e-07 | – | – |
uracil | – | – | – | – | 0.02 | – | – |
uridine monophosphate (UMP) | – | – | – | – | 2.26e-06 | – | – |
uridine diphosphate glucose | – | – | – | – | 5.65e-04 | – | – |
adenosine monophosphate | – | – | – | – | 1.22e-06 | – | – |
methylthioadenosine | – | – | – | – | 1.49e-03 | – | – |
methylthioadenosine | – | – | – | – | 2.57e-04 | – | – |
oxidized glutathione | – | – | – | – | 5.65e-04 | – | – |
xantine | – | – | – | – | 4.96e-04 | – | – |
hypoxanthine | – | – | – | – | 1.26e-03 | – | – |
lactic acid | – | – | – | – | 0.01 | – | – |
aminobutyric acid | – | – | – | – | 7.76e-04 | – | – |
lactic acid | – | – | – | – | 7.25e-06 | – | – |
malic acid | – | – | – | – | 6.18e-04 | – | – |
AMDA | – | – | – | – | 8.38e-04 | – | – |
bilirubin | – | – | – | – | 3.86e-06 | – | – |
bilirubin | – | – | – | – | 4.85e-08 | – | – |
creatinine | – | – | – | – | 2.88e-05 | – | – |
creatine | – | – | – | – | 4.68e-04 | – | – |
creatine | – | – | – | – | 5.07e-06 | – | – |
dihydrothymine | – | – | – | – | 0.01 | – | – |
dimethylglycine | – | – | – | – | 0.02 | – | – |
ethanolamine phosphate | – | – | – | – | 1.67e-05 | – | – |
ethanolamine phosphate | – | – | – | – | 1.05e-04 | – | – |
phosphoethanolamine | – | – | – | – | 1.10e-03 | – | – |
niacinamide | – | – | – | – | 4.77e-05 | – | – |
nicotinamide | – | – | – | – | 5.44e-04 | – | – |
acetylspermidine | – | – | – | – | 9.69e-04 | – | – |
phytosphingosine | – | – | – | – | 3.27e-03 | – | – |
sphingosine | – | – | – | – | 0.04 | – | – |
sphingosine | – | – | – | – | 1.65e-04 | – | – |
piperidine | – | – | – | – | 3.64e-03 | – | – |
adrenic acid | – | – | – | – | 1.69e-05 | – | – |
adrenic acid | – | – | – | – | 5.84e-04 | – | – |
docosahexaenoic acid | – | – | – | – | 5.18e-03 | – | – |
eicosadienoic acid | – | – | – | – | 4.81e-06 | – | – |
eicosapentaenoic acid | – | – | – | – | 0.05 | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | 1.83e-03 | – | – |
acetylcarnitine | – | – | – | – | 0.05 | – | – |
arachidonoylcarnitine | – | – | – | – | 0.02 | – | – |
butyrylcarnitine | – | – | – | – | 1.67e-03 | – | – |
butyrylcarnitine | – | – | – | – | 1.84e-03 | – | – |
carnitine | – | – | – | – | 0.02 | – | – |
eicosadienoylcarnitine | – | – | – | – | 9.22e-06 | – | – |
docosadienoylcarnitine | – | – | – | – | 2.98e-06 | – | – |
eicoseneoylcarnitine | – | – | – | – | 2.61e-04 | – | – |
heptadecanoyl carnitine | – | – | – | – | 1.23e-03 | – | – |
hexadecanoylcarnitine | – | – | – | – | 2.90e-04 | – | – |
Hexadecenoylcarnitine | – | – | – | – | 3.06e-04 | – | – |
Hexadecenoylcarnitine | – | – | – | – | 5.02e-03 | – | – |
hydroxybutyrylcarnitine | – | – | – | – | 2.63e-03 | – | – |
hydroxyhexadecanoylcarnitine | – | – | – | – | 0.02 | – | – |
hydroxymyristoylcarnitine | – | – | – | – | 7.02e-03 | – | – |
hydroxyoctadecenoylcarnitine | – | – | – | – | 1.97e-04 | – | – |
hydroxyoctanoyl carnitine | – | – | – | – | 0.02 | – | – |
hydroxytetradecenoylcarnitine | – | – | – | – | 1.05e-03 | – | – |
hydroxyvalerylcarnitine | – | – | – | – | 2.36e-06 | – | – |
octadecadienylcarnitine | – | – | – | – | 0.04 | – | – |
octadecadienylcarnitine | – | – | – | – | 1.06e-04 | – | – |
Octadecenoylcarnitine | – | – | – | – | 1.22e-04 | – | – |
Octadecenoylcarnitine | – | – | – | – | 3.78e-04 | – | – |
octanoylcarnitine | – | – | – | – | 0.04 | – | – |
Pentadecanoylcarnitine | – | – | – | – | 1.91e-05 | – | – |
propionylcarnitine | – | – | – | – | 0.02 | – | – |
tetradecanoylcarnitine | – | – | – | – | 9.08e-04 | – | – |
Tetradecenoylcarnitine | – | – | – | – | 8.98e-03 | – | – |
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0) | – | – | – | – | 4.38e-04 | – | – |
LysoPC 15:0 | – | – | – | – | 0.04 | – | – |
LysoPC 15:0 | – | – | – | – | 0.02 | – | – |
LysoPC 16:1 Plasm | – | – | – | – | 0.04 | – | – |
LysoPC 16:1 sn1 | – | – | – | – | 3.67e-04 | – | – |
LysoPC 16:1 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 16:1 sn2 | – | – | – | – | 2.55e-03 | – | – |
LysoPC 16:1 sn2 | – | – | – | – | 1.93e-03 | – | – |
LysoPC 18:1 sn2 | – | – | – | – | 2.22e-03 | – | – |
LysoPC 18:1 sn2 | – | – | – | – | 1.84e-04 | – | – |
LysoPC 18:2 sn2 | – | – | – | – | 4.49e-05 | – | – |
LysoPC 18:2 sn2 | – | – | – | – | 8.72e-05 | – | – |
LysoPC 20:1 | – | – | – | – | 3.90e-03 | – | – |
LysoPC 20:2 | – | – | – | – | 4.28e-07 | – | – |
LysoPC 20:2 | – | – | – | – | 1.41e-04 | – | – |
LysoPC 20:3 | – | – | – | – | 6.30e-03 | – | – |
LysoPC 20:3 sn1 | – | – | – | – | 9.29e-03 | – | – |
LysoPC 20:3 sn2 | – | – | – | – | 1.38e-05 | – | – |
LysoPC 20:4 | – | – | – | – | 0.02 | – | – |
LysoPC 22:6 sn2 | – | – | – | – | 2.78e-06 | – | – |
LysoPC 22:6 sn2 | – | – | – | – | 2.46e-06 | – | – |
LysoPC O-16:1 / LysoPC P-16:0 | – | – | – | – | 0.04 | – | – |
LysoPE 16:0 sn1 | – | – | – | – | 0.03 | – | – |
LysoPE 16:0 sn1 | – | – | – | – | 0.03 | – | – |
LysoPE 16:0 sn2 | – | – | – | – | 2.65e-03 | – | – |
LysoPE 16:0 sn2 | – | – | – | – | 0.04 | – | – |
LysoPE 16:1 | – | – | – | – | 7.91e-03 | – | – |
LysoPE 18:0 sn2 | – | – | – | – | 0.04 | – | – |
LysoPE 18:2 sn2 | – | – | – | – | 0.02 | – | – |
LysoPE 20:4 | – | – | – | – | 0.03 | – | – |
LysoPE 22:6 | – | – | – | – | 8.26e-03 | – | – |
LysoPE P-17:0 | – | – | – | – | 0.02 | – | – |
LysoPG 18:0 | – | – | – | – | 9.06e-03 | – | – |
LysoPG 18:1 sn1 | – | – | – | – | 2.93e-03 | – | – |
LysoPG 18:1 sn2 | – | – | – | – | 4.84e-03 | – | – |
LysoPI 18:1 sn2 | – | – | – | – | 0.04 | – | – |
LysoPI 18:2 | – | – | – | – | 0.02 | – | – |
LysoPI 20:3 sn1 | – | – | – | – | 4.03e-04 | – | – |
LysoPI 20:3 sn2 | – | – | – | – | 9.96e-06 | – | – |
LysoPI 20:4 sn2 | – | – | – | – | 6.38e-05 | – | – |
PC 14:0/22:6 | – | – | – | – | 0.04 | – | – |
PC 15:0/20:4 | – | – | – | – | 7.39e-04 | – | – |
PC 16:1/22:6 | – | – | – | – | 0.02 | – | – |
PC 17:0/20:4 | – | – | – | – | 0.01 | – | – |
PC 18:0/22:6 | – | – | – | – | 5.80e-05 | – | – |
PC 18:1/22:6 | – | – | – | – | 1.87e-03 | – | – |
PC 18:2/22:6 | – | – | – | – | 1.01e-03 | – | – |
PC 18:2/22:6 | – | – | – | – | 8.81e-03 | – | – |
PC 20:4/22:4 | – | – | – | – | 3.71e-05 | – | – |
PC 20:4/22:6 | – | – | – | – | 0.02 | – | – |
PC 35:1 | – | – | – | – | 0.05 | – | – |
PC 35:5 | – | – | – | – | 7.95e-05 | – | – |
PC 36:4 Plasm | – | – | – | – | 0.05 | – | – |
PC 36:6 | – | – | – | – | 6.35e-03 | – | – |
PC 38:3 | – | – | – | – | 0.03 | – | – |
PC 38:3 | – | – | – | – | 0.03 | – | – |
PC 38:5 | – | – | – | – | 3.70e-05 | – | – |
PC 38:5 | – | – | – | – | 0.02 | – | – |
PC 38:5 | – | – | – | – | 0.03 | – | – |
PC 40:6 | – | – | – | – | 0.03 | – | – |
PC 40:6 | – | – | – | – | 0.03 | – | – |
PC 42:8 | – | – | – | – | 2.89e-04 | – | – |
PC P-16:0/18:2 | – | – | – | – | 7.50e-03 | – | – |
PC P-18:0/22:6 | – | – | – | – | 4.86e-03 | – | – |
PE 32:2 | – | – | – | – | 0.03 | – | – |
SM 36:2 | – | – | – | – | 2.94e-03 | – | – |
SM (d18:1/18:0) | – | – | – | – | 0.02 | – | – |
SM(d18:0/16:0) | – | – | – | – | 0.02 | – | – |
SM(d18:1/12:0) | – | – | – | – | 0.02 | – | – |
SM(d18:1/12:0) | – | – | – | – | 0.03 | – | – |
valine | – | – | – | – | 0.01 | – | – |
acetylaspartic acid | – | – | – | – | 0.03 | – | – |
hydroxyglutaric acid | – | – | – | – | 0.03 | – | – |
taurine | – | – | – | – | 0.05 | – | – |
taurine | – | – | – | – | 0.02 | – | – |
taurine | – | – | – | – | 0.04 | – | – |
guanosine | – | – | – | – | 1.85e-03 | – | – |
inosine | – | – | – | – | 0.02 | – | – |
xantine | – | – | – | – | 0.04 | – | – |
L-threonic acid/hypoxanthine | – | – | – | – | 0.03 | – | – |
uric acid | – | – | – | – | 0.03 | – | – |
creatinine | – | – | – | – | 0.02 | – | – |
creatine | – | – | – | – | 9.83e-03 | – | – |
creatine | – | – | – | – | 4.07e-03 | – | – |
dihydrothymine | – | – | – | – | 0.03 | – | – |
ethanolamine phosphate | – | – | – | – | 0.05 | – | – |
ethanolamine phosphate | – | – | – | – | 0.02 | – | – |
trimethylamine | – | – | – | – | 0.04 | – | – |
Glycerophospho-(N-acyl)-ethanolamine | – | – | – | – | 0.02 | – | – |
glycerophospho-N-heptacenyl ethanolamine | – | – | – | – | 0.01 | – | – |
Glycerophospho-N-heptadecanoyl Ethanolamine | – | – | – | – | 7.88e-03 | – | – |
Glycerophospho-N-hexadecenyl Ethanolamine | – | – | – | – | 0.02 | – | – |
glycerophospho-N-octadecanoyl ethanolamine | – | – | – | – | 0.01 | – | – |
Glycerophospho-N-octadecenyl Ethanolamine | – | – | – | – | 0.05 | – | – |
arachidonic acid | – | – | – | – | 0.03 | – | – |
arachidonic acid | – | – | – | – | 0.02 | – | – |
arachidonic acid | – | – | – | – | 0.03 | – | – |
docosahexaenoic acid | – | – | – | – | 0.03 | – | – |
eicosapentaenoic acid | – | – | – | – | 0.02 | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | 0.03 | – | – |
carnitine | – | – | – | – | 0.02 | – | – |
hydroxyoctanoyl carnitine | – | – | – | – | 0.03 | – | – |
octadecadienylcarnitine | – | – | – | – | 0.01 | – | – |
LysoPA 18:1 | – | – | – | – | 0.03 | – | – |
LysoPC 15:0 | – | – | – | – | 0.01 | – | – |
LysoPC 15:0 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.02 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.03 | – | – |
LysoPC 16:0 sn2 | – | – | – | – | 0.02 | – | – |
LysoPC 16:1 Plasm | – | – | – | – | 0.02 | – | – |
LysoPC 17:0 | – | – | – | – | 0.01 | – | – |
LysoPC 17:0 | – | – | – | – | 0.02 | – | – |
LysoPC 18:0 | – | – | – | – | 0.02 | – | – |
LysoPC 18:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 18:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPC 18:0 sn2 | – | – | – | – | 0.02 | – | – |
LysoPC 18:0 sn2 | – | – | – | – | 0.04 | – | – |
LysoPC 18:1 sn1 | – | – | – | – | 0.03 | – | – |
LysoPC 18:1 sn1 | – | – | – | – | 0.04 | – | – |
LysoPC 18:2 | – | – | – | – | 0.02 | – | – |
LysoPC 18:2 sn1 | – | – | – | – | 0.04 | – | – |
LysoPC 18:2 sn1 | – | – | – | – | 0.05 | – | – |
LysoPC 18:2 sn2 | – | – | – | – | 0.05 | – | – |
LysoPE 16:0 sn1 | – | – | – | – | 0.03 | – | – |
LysoPE 16:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPE 16:0 sn2 | – | – | – | – | 0.02 | – | – |
LysoPE 17:0 | – | – | – | – | 0.02 | – | – |
LysoPE 18:0 sn1 | – | – | – | – | 0.02 | – | – |
LysoPE 18:0 sn2 | – | – | – | – | 0.04 | – | – |
LysoPE 18:1 | – | – | – | – | 0.02 | – | – |
LysoPE 18:2 sn1 | – | – | – | – | 0.03 | – | – |
LysoPE 22:4 | – | – | – | – | 0.04 | – | – |
LysoPE 22:5 | – | – | – | – | 0.02 | – | – |
LysoPE P-16:0 | – | – | – | – | 0.02 | – | – |
LysoPI 16:0 | – | – | – | – | 0.02 | – | – |
LysoPI 18:0 | – | – | – | – | 0.04 | – | – |
LysoPI 18:1 sn1 | – | – | – | – | 0.04 | – | – |
LysoPI 18:2 | – | – | – | – | 0.05 | – | – |
LysoPI 20:3 | – | – | – | – | 0.04 | – | – |
PC 16:1/20:4 | – | – | – | – | 0.02 | – | – |
PE 17:0/20:4 | – | – | – | – | 0.04 | – | – |
SM 36:2 | – | – | – | – | 0.05 | – | – |
PC 40:7 | – | – | – | – | 0.02 | – | – |
PE P-16:0/18:2 | – | – | – | – | 0.02 | – | – |
PC 36:0 Plasm | – | – | – | – | 0.03 | – | – |
LysoPC 18:3 | – | – | – | – | 0.03 | – | – |
PE P-16:0/18:2 | – | – | – | – | 9.55e-04 | – | – |
SM(d18:2/15:0) | – | – | – | – | 0.02 | – | – |
PE P-18:1/20:4; PE P-16:0/22:5 | – | – | – | – | 0.03 | – | – |
PE 20:4/P-18:0 | – | – | – | – | 2.56e-03 | – | – |
PC O-16:1/18:2 | – | – | – | – | 9.55e-04 | – | – |
PC 20:5/P-16:0 | – | – | – | – | 0.02 | – | – |
PC 15:0/22:6 | – | – | – | – | 0.02 | – | – |
PC 18:1/22:6 | – | – | – | – | 0.02 | – | – |
Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
---|---|---|---|---|---|---|
arginine | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
leucine/isoleucine | – | – | – | – | – | – |
phenylalanine | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
tryphophan | – | – | – | – | – | – |
tyrosine | – | – | – | – | – | – |
methylhistidine | – | – | – | – | – | – |
acetylaspartic acid | – | – | – | – | – | – |
pyroglutamic acid | – | – | – | – | – | – |
pyroglutamic acid | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
guanosine | – | – | – | – | – | – |
guanosine monophosphate | – | – | – | – | – | – |
inosine | – | – | – | – | – | – |
uracil | – | – | – | – | – | – |
uridine monophosphate (UMP) | – | – | – | – | – | – |
uridine diphosphate glucose | – | – | – | – | – | – |
adenosine monophosphate | – | – | – | – | – | – |
methylthioadenosine | – | – | – | – | – | – |
methylthioadenosine | – | – | – | – | – | – |
oxidized glutathione | – | – | – | – | – | – |
xantine | – | – | – | – | – | – |
hypoxanthine | – | – | – | – | – | – |
L-threonic acid/hypoxanthine | – | – | – | – | – | – |
lactic acid | – | – | – | – | – | – |
aminobutyric acid | – | – | – | – | – | – |
acetylneuraminic acid | – | – | – | – | – | – |
Dipicolinic acid (DPA) | – | – | – | – | – | – |
lactic acid | – | – | – | – | – | – |
malic acid | – | – | – | – | – | – |
uric acid | – | – | – | – | – | – |
AMDA | – | – | – | – | – | – |
bilirubin | – | – | – | – | – | – |
bilirubin | – | – | – | – | – | – |
creatinine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
dihydrothymine | – | – | – | – | – | – |
dimethylglycine | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
phosphoethanolamine | – | – | – | – | – | – |
niacinamide | – | – | – | – | – | – |
nicotinamide | – | – | – | – | – | – |
stearamide | – | – | – | – | – | – |
trimethylamine | – | – | – | – | – | – |
glucose-6-phosphate | – | – | – | – | – | – |
diacetylspermine | – | – | – | – | – | – |
acetylspermidine | – | – | – | – | – | – |
phytosphingosine | – | – | – | – | – | – |
sphingosine | – | – | – | – | – | – |
sphingosine | – | – | – | – | – | – |
Glycerophospho-N-hexadecenyl Ethanolamine | – | – | – | – | – | – |
adrenic acid | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
docosahexaenoic acid | – | – | – | – | – | – |
eicosadienoic acid | – | – | – | – | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | – | – |
oleic acid | – | – | – | – | – | – |
palmitic acid | – | – | – | – | – | – |
arachidoyl carnitine | – | – | – | – | – | – |
arachidonoylcarnitine | – | – | – | – | – | – |
butyrylcarnitine | – | – | – | – | – | – |
butyrylcarnitine | – | – | – | – | – | – |
eicosadienoylcarnitine | – | – | – | – | – | – |
docosadienoylcarnitine | – | – | – | – | – | – |
eicoseneoylcarnitine | – | – | – | – | – | – |
heptadecanoyl carnitine | – | – | – | – | – | – |
hexadecanoylcarnitine | – | – | – | – | – | – |
Hexadecenoylcarnitine | – | – | – | – | – | – |
hydroxyhexanoylcarnitine | – | – | – | – | – | – |
hydroxyoctadecenoylcarnitine | – | – | – | – | – | – |
hydroxyvalerylcarnitine | – | – | – | – | – | – |
octadecadienylcarnitine | – | – | – | – | – | – |
Octadecenoylcarnitine | – | – | – | – | – | – |
octanoylcarnitine | – | – | – | – | – | – |
Pentadecanoylcarnitine | – | – | – | – | – | – |
stearoylcarnitine | – | – | – | – | – | – |
tetradecanoylcarnitine | – | – | – | – | – | – |
Tetradecenoylcarnitine | – | – | – | – | – | – |
valerylcarnitine | – | – | – | – | – | – |
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0) | – | – | – | – | – | – |
LysoPA 18:1 | – | – | – | – | – | – |
LysoPC 14:0 | – | – | – | – | – | – |
LysoPC 14:0 | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 16:0 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:1 sn1 | – | – | – | – | – | – |
LysoPC 16:1 sn2 | – | – | – | – | – | – |
LysoPC 16:1 sn2 | – | – | – | – | – | – |
LysoPC 17:0 | – | – | – | – | – | – |
LysoPC 17:0 | – | – | – | – | – | – |
LysoPC 18:1 sn1 | – | – | – | – | – | – |
LysoPC 18:1 sn1 | – | – | – | – | – | – |
LysoPC 18:1 sn2 | – | – | – | – | – | – |
LysoPC 18:2 | – | – | – | – | – | – |
LysoPC 18:2 sn1 | – | – | – | – | – | – |
LysoPC 18:2 sn1 | – | – | – | – | – | – |
LysoPC 18:2 sn2 | – | – | – | – | – | – |
LysoPC 18:2 sn2 | – | – | – | – | – | – |
LysoPC 20:2 | – | – | – | – | – | – |
LysoPC 20:2 | – | – | – | – | – | – |
LysoPC 20:3 | – | – | – | – | – | – |
LysoPC 20:3 sn1 | – | – | – | – | – | – |
LysoPC 20:3 sn2 | – | – | – | – | – | – |
LysoPC 20:4 | – | – | – | – | – | – |
LysoPC 20:4 | – | – | – | – | – | – |
LysoPC 22:6 sn1 | – | – | – | – | – | – |
LysoPC 22:6 sn1 | – | – | – | – | – | – |
LysoPC 22:6 sn2 | – | – | – | – | – | – |
LysoPC 22:6 sn2 | – | – | – | – | – | – |
LysoPE 18:2 sn2 | – | – | – | – | – | – |
LysoPE 22:5 | – | – | – | – | – | – |
LysoPE P-16:0 | – | – | – | – | – | – |
LysoPE P-17:0 | – | – | – | – | – | – |
LysoPG 18:0 | – | – | – | – | – | – |
LysoPG 18:1 sn1 | – | – | – | – | – | – |
LysoPG 18:1 sn2 | – | – | – | – | – | – |
LysoPG 18:2 | – | – | – | – | – | – |
LysoPG 20:4 | – | – | – | – | – | – |
LysoPG 22:6 | – | – | – | – | – | – |
LysoPI 16:0 | – | – | – | – | – | – |
LysoPI 18:0 | – | – | – | – | – | – |
LysoPI 18:1 sn1 | – | – | – | – | – | – |
LysoPI 18:2 | – | – | – | – | – | – |
LysoPI 20:3 | – | – | – | – | – | – |
LysoPI 20:3 sn2 | – | – | – | – | – | – |
LysoPI 20:4 sn2 | – | – | – | – | – | – |
PC 14:0/18:2; PC 16:1/16:1 | – | – | – | – | – | – |
PC 14:0/22:6 | – | – | – | – | – | – |
PC 15:0/20:4 | – | – | – | – | – | – |
PC 16:0/18:2 | – | – | – | – | – | – |
PC 16:1/20:4 | – | – | – | – | – | – |
PC 16:1/22:6 | – | – | – | – | – | – |
PC 17:0/20:4 | – | – | – | – | – | – |
PC 18:0/22:6 | – | – | – | – | – | – |
PC 18:1/22:6 | – | – | – | – | – | – |
PC 18:1/22:6 | – | – | – | – | – | – |
PC 18:2/22:6 | – | – | – | – | – | – |
PC 18:2/22:6 | – | – | – | – | – | – |
PC 20:4/14:0 | – | – | – | – | – | – |
PC 20:4/22:4 | – | – | – | – | – | – |
PC 29:0 | – | – | – | – | – | – |
PC 34:1 Plasm | – | – | – | – | – | – |
PC 35:1 | – | – | – | – | – | – |
PC 35:5 | – | – | – | – | – | – |
PC 36:6 | – | – | – | – | – | – |
PC 38:3 | – | – | – | – | – | – |
PC 38:3 | – | – | – | – | – | – |
PC 38:5 | – | – | – | – | – | – |
PC 38:5 | – | – | – | – | – | – |
PC 40:6 | – | – | – | – | – | – |
PC 40:6 Plasm | – | – | – | – | – | – |
PC 40:8 | – | – | – | – | – | – |
PC 40:9 | – | – | – | – | – | – |
PC 42:8 | – | – | – | – | – | – |
PC P-18:0/22:6 | – | – | – | – | – | – |
PC P-18:1/20:4 | – | – | – | – | – | – |
PE 16:0/22:6 | – | – | – | – | – | – |
PE 17:0/20:4 | – | – | – | – | – | – |
PE 32:2 | – | – | – | – | – | – |
PE 36:5 | – | – | – | – | – | – |
SM 32:1 | – | – | – | – | – | – |
SM 35:1 | – | – | – | – | – | – |
SM 35:1 | – | – | – | – | – | – |
SM (d18:1/18:0) | – | – | – | – | – | – |
SM(d18:0/16:0) | – | – | – | – | – | – |
SM(d18:1/12:0) | – | – | – | – | – | – |
SM(d18:1/12:0) | – | – | – | – | – | – |
SM(d18:2/14:0) | – | – | – | – | – | – |
SM(d18:2/14:0) | – | – | – | – | – | – |
SM(d18:2/15:0) | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamic acid | – | – | – | – | – | – |
glutamine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
histidine | – | – | – | – | – | – |
leucine | – | – | – | – | – | – |
leucine/isoleucine | – | – | – | – | – | – |
phenylalanine | – | – | – | – | – | – |
phenylalanine | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
proline | – | – | – | – | – | – |
tryphophan | – | – | – | – | – | – |
tyrosine | – | – | – | – | – | – |
valine | – | – | – | – | – | – |
methylhistidine | – | – | – | – | – | – |
acetylaspartic acid | – | – | – | – | – | – |
pyroglutamic acid | – | – | – | – | – | – |
hydroxyglutaric acid | – | – | – | – | – | – |
betaina | – | – | – | – | – | – |
betaine | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
glutathione | – | – | – | – | – | – |
guanosine | – | – | – | – | – | – |
guanosine monophosphate | – | – | – | – | – | – |
uracil | – | – | – | – | – | – |
uridine monophosphate (UMP) | – | – | – | – | – | – |
uridine diphosphate glucose | – | – | – | – | – | – |
adenosine monophosphate | – | – | – | – | – | – |
methylthioadenosine | – | – | – | – | – | – |
methylthioadenosine | – | – | – | – | – | – |
oxidized glutathione | – | – | – | – | – | – |
xantine | – | – | – | – | – | – |
hypoxanthine | – | – | – | – | – | – |
lactic acid | – | – | – | – | – | – |
aminobutyric acid | – | – | – | – | – | – |
lactic acid | – | – | – | – | – | – |
malic acid | – | – | – | – | – | – |
AMDA | – | – | – | – | – | – |
bilirubin | – | – | – | – | – | – |
bilirubin | – | – | – | – | – | – |
creatinine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
dihydrothymine | – | – | – | – | – | – |
dimethylglycine | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
phosphoethanolamine | – | – | – | – | – | – |
niacinamide | – | – | – | – | – | – |
nicotinamide | – | – | – | – | – | – |
acetylspermidine | – | – | – | – | – | – |
phytosphingosine | – | – | – | – | – | – |
sphingosine | – | – | – | – | – | – |
sphingosine | – | – | – | – | – | – |
piperidine | – | – | – | – | – | – |
adrenic acid | – | – | – | – | – | – |
adrenic acid | – | – | – | – | – | – |
docosahexaenoic acid | – | – | – | – | – | – |
eicosadienoic acid | – | – | – | – | – | – |
eicosapentaenoic acid | – | – | – | – | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | – | – |
acetylcarnitine | – | – | – | – | – | – |
arachidonoylcarnitine | – | – | – | – | – | – |
butyrylcarnitine | – | – | – | – | – | – |
butyrylcarnitine | – | – | – | – | – | – |
carnitine | – | – | – | – | – | – |
eicosadienoylcarnitine | – | – | – | – | – | – |
docosadienoylcarnitine | – | – | – | – | – | – |
eicoseneoylcarnitine | – | – | – | – | – | – |
heptadecanoyl carnitine | – | – | – | – | – | – |
hexadecanoylcarnitine | – | – | – | – | – | – |
Hexadecenoylcarnitine | – | – | – | – | – | – |
Hexadecenoylcarnitine | – | – | – | – | – | – |
hydroxybutyrylcarnitine | – | – | – | – | – | – |
hydroxyhexadecanoylcarnitine | – | – | – | – | – | – |
hydroxymyristoylcarnitine | – | – | – | – | – | – |
hydroxyoctadecenoylcarnitine | – | – | – | – | – | – |
hydroxyoctanoyl carnitine | – | – | – | – | – | – |
hydroxytetradecenoylcarnitine | – | – | – | – | – | – |
hydroxyvalerylcarnitine | – | – | – | – | – | – |
octadecadienylcarnitine | – | – | – | – | – | – |
octadecadienylcarnitine | – | – | – | – | – | – |
Octadecenoylcarnitine | – | – | – | – | – | – |
Octadecenoylcarnitine | – | – | – | – | – | – |
octanoylcarnitine | – | – | – | – | – | – |
Pentadecanoylcarnitine | – | – | – | – | – | – |
propionylcarnitine | – | – | – | – | – | – |
tetradecanoylcarnitine | – | – | – | – | – | – |
Tetradecenoylcarnitine | – | – | – | – | – | – |
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0) | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 16:1 Plasm | – | – | – | – | – | – |
LysoPC 16:1 sn1 | – | – | – | – | – | – |
LysoPC 16:1 sn1 | – | – | – | – | – | – |
LysoPC 16:1 sn2 | – | – | – | – | – | – |
LysoPC 16:1 sn2 | – | – | – | – | – | – |
LysoPC 18:1 sn2 | – | – | – | – | – | – |
LysoPC 18:1 sn2 | – | – | – | – | – | – |
LysoPC 18:2 sn2 | – | – | – | – | – | – |
LysoPC 18:2 sn2 | – | – | – | – | – | – |
LysoPC 20:1 | – | – | – | – | – | – |
LysoPC 20:2 | – | – | – | – | – | – |
LysoPC 20:2 | – | – | – | – | – | – |
LysoPC 20:3 | – | – | – | – | – | – |
LysoPC 20:3 sn1 | – | – | – | – | – | – |
LysoPC 20:3 sn2 | – | – | – | – | – | – |
LysoPC 20:4 | – | – | – | – | – | – |
LysoPC 22:6 sn2 | – | – | – | – | – | – |
LysoPC 22:6 sn2 | – | – | – | – | – | – |
LysoPC O-16:1 / LysoPC P-16:0 | – | – | – | – | – | – |
LysoPE 16:0 sn1 | – | – | – | – | – | – |
LysoPE 16:0 sn1 | – | – | – | – | – | – |
LysoPE 16:0 sn2 | – | – | – | – | – | – |
LysoPE 16:0 sn2 | – | – | – | – | – | – |
LysoPE 16:1 | – | – | – | – | – | – |
LysoPE 18:0 sn2 | – | – | – | – | – | – |
LysoPE 18:2 sn2 | – | – | – | – | – | – |
LysoPE 20:4 | – | – | – | – | – | – |
LysoPE 22:6 | – | – | – | – | – | – |
LysoPE P-17:0 | – | – | – | – | – | – |
LysoPG 18:0 | – | – | – | – | – | – |
LysoPG 18:1 sn1 | – | – | – | – | – | – |
LysoPG 18:1 sn2 | – | – | – | – | – | – |
LysoPI 18:1 sn2 | – | – | – | – | – | – |
LysoPI 18:2 | – | – | – | – | – | – |
LysoPI 20:3 sn1 | – | – | – | – | – | – |
LysoPI 20:3 sn2 | – | – | – | – | – | – |
LysoPI 20:4 sn2 | – | – | – | – | – | – |
PC 14:0/22:6 | – | – | – | – | – | – |
PC 15:0/20:4 | – | – | – | – | – | – |
PC 16:1/22:6 | – | – | – | – | – | – |
PC 17:0/20:4 | – | – | – | – | – | – |
PC 18:0/22:6 | – | – | – | – | – | – |
PC 18:1/22:6 | – | – | – | – | – | – |
PC 18:2/22:6 | – | – | – | – | – | – |
PC 18:2/22:6 | – | – | – | – | – | – |
PC 20:4/22:4 | – | – | – | – | – | – |
PC 20:4/22:6 | – | – | – | – | – | – |
PC 35:1 | – | – | – | – | – | – |
PC 35:5 | – | – | – | – | – | – |
PC 36:4 Plasm | – | – | – | – | – | – |
PC 36:6 | – | – | – | – | – | – |
PC 38:3 | – | – | – | – | – | – |
PC 38:3 | – | – | – | – | – | – |
PC 38:5 | – | – | – | – | – | – |
PC 38:5 | – | – | – | – | – | – |
PC 38:5 | – | – | – | – | – | – |
PC 40:6 | – | – | – | – | – | – |
PC 40:6 | – | – | – | – | – | – |
PC 42:8 | – | – | – | – | – | – |
PC P-16:0/18:2 | – | – | – | – | – | – |
PC P-18:0/22:6 | – | – | – | – | – | – |
PE 32:2 | – | – | – | – | – | – |
SM 36:2 | – | – | – | – | – | – |
SM (d18:1/18:0) | – | – | – | – | – | – |
SM(d18:0/16:0) | – | – | – | – | – | – |
SM(d18:1/12:0) | – | – | – | – | – | – |
SM(d18:1/12:0) | – | – | – | – | – | – |
valine | – | – | – | – | – | – |
acetylaspartic acid | – | – | – | – | – | – |
hydroxyglutaric acid | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
taurine | – | – | – | – | – | – |
guanosine | – | – | – | – | – | – |
inosine | – | – | – | – | – | – |
xantine | – | – | – | – | – | – |
L-threonic acid/hypoxanthine | – | – | – | – | – | – |
uric acid | – | – | – | – | – | – |
creatinine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
creatine | – | – | – | – | – | – |
dihydrothymine | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
ethanolamine phosphate | – | – | – | – | – | – |
trimethylamine | – | – | – | – | – | – |
Glycerophospho-(N-acyl)-ethanolamine | – | – | – | – | – | – |
glycerophospho-N-heptacenyl ethanolamine | – | – | – | – | – | – |
Glycerophospho-N-heptadecanoyl Ethanolamine | – | – | – | – | – | – |
Glycerophospho-N-hexadecenyl Ethanolamine | – | – | – | – | – | – |
glycerophospho-N-octadecanoyl ethanolamine | – | – | – | – | – | – |
Glycerophospho-N-octadecenyl Ethanolamine | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
arachidonic acid | – | – | – | – | – | – |
docosahexaenoic acid | – | – | – | – | – | – |
eicosapentaenoic acid | – | – | – | – | – | – |
Eicosatrienoic acid (ETrE) | – | – | – | – | – | – |
carnitine | – | – | – | – | – | – |
hydroxyoctanoyl carnitine | – | – | – | – | – | – |
octadecadienylcarnitine | – | – | – | – | – | – |
LysoPA 18:1 | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 15:0 | – | – | – | – | – | – |
LysoPC 16:0 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn1 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:0 sn2 | – | – | – | – | – | – |
LysoPC 16:1 Plasm | – | – | – | – | – | – |
LysoPC 17:0 | – | – | – | – | – | – |
LysoPC 17:0 | – | – | – | – | – | – |
LysoPC 18:0 | – | – | – | – | – | – |
LysoPC 18:0 sn1 | – | – | – | – | – | – |
LysoPC 18:0 sn1 | – | – | – | – | – | – |
LysoPC 18:0 sn2 | – | – | – | – | – | – |
LysoPC 18:0 sn2 | – | – | – | – | – | – |
LysoPC 18:1 sn1 | – | – | – | – | – | – |
LysoPC 18:1 sn1 | – | – | – | – | – | – |
LysoPC 18:2 | – | – | – | – | – | – |
LysoPC 18:2 sn1 | – | – | – | – | – | – |
LysoPC 18:2 sn1 | – | – | – | – | – | – |
LysoPC 18:2 sn2 | – | – | – | – | – | – |
LysoPE 16:0 sn1 | – | – | – | – | – | – |
LysoPE 16:0 sn1 | – | – | – | – | – | – |
LysoPE 16:0 sn2 | – | – | – | – | – | – |
LysoPE 17:0 | – | – | – | – | – | – |
LysoPE 18:0 sn1 | – | – | – | – | – | – |
LysoPE 18:0 sn2 | – | – | – | – | – | – |
LysoPE 18:1 | – | – | – | – | – | – |
LysoPE 18:2 sn1 | – | – | – | – | – | – |
LysoPE 22:4 | – | – | – | – | – | – |
LysoPE 22:5 | – | – | – | – | – | – |
LysoPE P-16:0 | – | – | – | – | – | – |
LysoPI 16:0 | – | – | – | – | – | – |
LysoPI 18:0 | – | – | – | – | – | – |
LysoPI 18:1 sn1 | – | – | – | – | – | – |
LysoPI 18:2 | – | – | – | – | – | – |
LysoPI 20:3 | – | – | – | – | – | – |
PC 16:1/20:4 | – | – | – | – | – | – |
PE 17:0/20:4 | – | – | – | – | – | – |
SM 36:2 | – | – | – | – | – | – |
PC 40:7 | – | – | – | – | – | – |
PE P-16:0/18:2 | – | – | – | – | – | – |
PC 36:0 Plasm | – | – | – | – | – | – |
LysoPC 18:3 | – | – | – | – | – | – |
PE P-16:0/18:2 | – | – | – | – | – | – |
SM(d18:2/15:0) | – | – | – | – | – | – |
PE P-18:1/20:4; PE P-16:0/22:5 | – | – | – | – | – | – |
PE 20:4/P-18:0 | – | – | – | – | – | – |
PC O-16:1/18:2 | – | – | – | – | – | – |
PC 20:5/P-16:0 | – | – | – | – | – | – |
PC 15:0/22:6 | – | – | – | – | – | – |
PC 18:1/22:6 | – | – | – | – | – | – |